Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Licenses Rosetta Resolver Gene Expression System

NEW YORK, Dec 29 – Paradigm genetics has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics and Agilent Technologies, the companies announced Friday.

The companies did not disclose the financial terms of the agreement. Agilent has been the exclusive distributor of the Rosetta Resolver, a bioinformatics gene expression analysis system that can be used with a variety of microarrays, since December 1999.

Rosetta has previously licensed the Resolver, which it launched in its newest version October 3, to Glaxo Wellcome and the Harvard Center for Genomics Research. Rosetta also recently opened a new gene expression profiling facility in Bothell, Wash.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.